Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28234661 | 0.97 | DNM1 (0.46) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL18107274 | 0.97 | DNM1 (0.52) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL18107273 | 0.97 | DNM1 (0.52) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL18107347 | 0.97 | DNM1 (0.52) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL14028946 | 0.97 | DNM1 (0.52) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL9751616 | 0.97 | DNM1 (0.52) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL12328082 | 0.97 | DNM1 (0.52) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL7532284 | 0.97 | LCK (0.48) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| Phosphine SCHEMBL10882704 | 0.94 | DNM1 (0.50) | DNM1LCKPPARDZDHHC20ZDHHC2 | |
| Phosphine SCHEMBL19411902 | 0.94 | DNM1 (0.50) | DNM1LCKPPARDZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431630-A | Biquaternary ammonium salt resin and preparation method and application thereof | 南京科技职业学院 | 2025-02-14 | — | — | CN | disclosed |
| US-20170342031-A1 | QUENCHER | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-11-30 | — | — | US | disclosed |
| US-9738738-B2 | Polymers functionalized with activated nitrogen heterocycles containing a pendant functional group | BRIDGESTONE CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160289355-A1 | POLYMERS FUNCTIONALIZED WITH ACTIVATED NITROGEN HETEROCYCLES CONTAINING A PENDANT FUNCTIONAL GROUP | BRIDGESTONE CORPORATION (JP) | 2016-10-06 | — | — | US | disclosed |
| US-9388172-B2 | Substituted carbamate compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| CN-105331447-A | Sterilizing cleaning composition with rich and stable foam | LI BIDAN | 2016-02-17 | — | — | CN | disclosed |
| EP-2917208-A1 | [3-HETEROARYL-2-TRIFLUOROMETHYL-PROPYL]-PIPERIDIN-1-YLE OR -MORPHOLIN-4-YLE COMPOUNDS AS TRPA1 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-20150239873-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-27 | — | — | US | disclosed |
| WO-2014072325-A1 | [3-HETEROARYL-2-TRIFLUOROMETHYL-PROPYL]-PIPERIDIN-1-YLE OR -MORPHOLIN-4-YLE COMPOUNDS AS TRPA1 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-8404731-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6933303-B2 | Heteroaryl-fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050096335-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. | 2005-05-05 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1438310-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TransTech Pharma Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | VTVX HOLDINGS I LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | DNM1 2613/4885LCK 92/4885PPARD 2359/4885 |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | DNM1 2495/4885LCK 79/4885PPARD 1845/4885 |
| US-20050096335-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | DNM1 2495/4885LCK 79/4885PPARD 1845/4885 |
| US-20150239873-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV5 | DNM1 3278/4885LCK 1336/4885PPARD 1134/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | DNM1 3272/4885LCK 97/4885PPARD 2749/4885 |
| US-20170342031-A1 | QUENCHER | AHR, GFER, AKR1A1 | DNM1 2437/4885LCK 4140/4885PPARD 2094/4885 |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | DNM1 2613/4885LCK 92/4885PPARD 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.